Review
doi: 10.2174/138955707782110178.
Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity
Affiliations
- PMID: 17979809
- DOI: 10.2174/138955707782110178
Item in Clipboard
Review
Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity
Mini Rev Med Chem.
2007 Oct.
Abstract
Depsipeptide (FK228), a new histone deacetylase inhibitor, has been recently introduced into clinical trials. This agent shows interesting metabolic properties, novel mechanism of action, and is undergoing phase I-II clinical studies in hematopoietic malignancies and solid tumors. Mechanism of action, pharmacokinetics and anticancer activity of depsipeptide is the subject of this review.
Similar articles
-
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.Cancer Chemother Pharmacol. 2006 Nov;58(5):711-5. doi: 10.1007/s00280-005-0182-5. Epub 2006 Jan 25. Cancer Chemother Pharmacol. 2006. PMID: 16435156 Review.
-
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.Clin Cancer Res. 2006 Jan 1;12(1):223-34. doi: 10.1158/1078-0432.CCR-05-1225. Clin Cancer Res. 2006. PMID: 16397046
-
Effect of a histone deacetylase inhibitor on human cardiac mass.Cardiovasc Drugs Ther. 2005 Jan;19(1):89-90. doi: 10.1007/s10557-005-6901-7. Cardiovasc Drugs Ther. 2005. PMID: 15883760 No abstract available.
-
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.J Clin Oncol. 2006 Aug 1;24(22):3678-85. doi: 10.1200/JCO.2006.06.4964. J Clin Oncol. 2006. PMID: 16877737 Clinical Trial.
-
Histone deacetylase inhibitors in cancer therapy.Cancer Invest. 2006 Aug-Sep;24(5):521-7. doi: 10.1080/07357900600814979. Cancer Invest. 2006. PMID: 16939962 Review. No abstract available.
Cited by
-
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.Cancer Biol Ther. 2010 Jun 1;9(11):928-35. doi: 10.4161/cbt.9.11.11873. Epub 2010 Jun 25. Cancer Biol Ther. 2010. PMID: 20404564 Free PMC article.
-
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy.Genes Cancer. 2015 May;6(5-6):184-213. doi: 10.18632/genesandcancer.65. Genes Cancer. 2015. PMID: 26124919 Free PMC article. Review.
-
Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.Invest New Drugs. 2010 Dec;28 Suppl 1(Suppl 1):S58-78. doi: 10.1007/s10637-010-9591-3. Epub 2010 Dec 4. Invest New Drugs. 2010. PMID: 21132350 Free PMC article.
-
Deacetylase inhibitors - focus on non-histone targets and effects.World J Biol Chem. 2010 May 26;1(5):55-61. doi: 10.4331/wjbc.v1.i5.55. World J Biol Chem. 2010. PMID: 21540990 Free PMC article.
-
Discovery and mechanism of natural products as modulators of histone acetylation.Curr Drug Targets. 2012 Jul;13(8):1029-47. doi: 10.2174/138945012802008973. Curr Drug Targets. 2012. PMID: 22594471 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
